Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Rhea-AI Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) announced publication of Phase 1 pharmacokinetic studies of TONMYA (TNX-102 SL), a sublingual cyclobenzaprine formulation FDA-approved Aug 15, 2025 and commercially launched Nov 2025. Two single-dose studies (n=24 and n=16) showed rapid transmucosal absorption, 154% relative bioavailability versus oral IR, ~3-minute absorption lag versus ~37 minutes, a 783% higher dose-normalized AUC in the first hour, dose proportionality, no food effect, and a norcyclobenzaprine elimination half-life of ~60 hours. Single doses were generally well tolerated; common AEs included oral hypoesthesia and abnormal taste.

Positive

• FDA approval on Aug 15, 2025
• U.S. commercial launch in Nov 2025
• 154% relative bioavailability vs oral IR
• Absorption lag of ~3 minutes vs ~37 minutes
• 783% higher dose-normalized AUC in first hour
• No food effect; dose proportionality confirmed

Negative

• Active metabolite norcyclobenzaprine elimination half-life ~60 hours
• Common adverse events: oral hypoesthesia and abnormal taste

News Market Reaction – TNXP

-1.97%

1 alert

-1.97% News Effect

-$3M Valuation Impact

$167M Market Cap

0.1x Rel. Volume

On the day this news was published, TNXP declined 1.97%, reflecting a mild negative market reaction. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $167M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Study 1 sample size: 24 healthy volunteers Dose levels (Study 1): 2.8 mg sublingual vs 5 mg oral IR Relative bioavailability: 154% +5 more

8 metrics

Study 1 sample size 24 healthy volunteers Phase 1, single-dose, open-label pharmacokinetic study

Dose levels (Study 1) 2.8 mg sublingual vs 5 mg oral IR Cyclobenzaprine HCl formulations compared under fasting conditions

Relative bioavailability 154% TNX-102 SL vs oral immediate-release cyclobenzaprine HCl

Absorption lag times 3 vs 37 minutes Sublingual TNX-102 SL vs oral IR cyclobenzaprine HCl

Early AUC increase 783% higher (dose-normalized) AUC during first hour post-dose vs oral IR

Study 2 sample size 16 healthy volunteers Crossover design under fasting and fed conditions

Dose levels (Study 2) 2.8 mg and 5.6 mg TNX-102 SL evaluated for dose proportionality and food effect

Norcyclobenzaprine half-life 60 hours (approx.) Elimination half-life of active metabolite in Study 2

Market Reality Check

Price: $13.45 Vol: Volume 336,621 is similar...

normal vol

$13.45 Last Close

Volume Volume 336,621 is similar to 20-day average 336,510, suggesting typical trading interest pre-publication. normal

Technical Shares at 13.98 trade below the 200-day MA 26.38, sitting between the 52-week low 6.76 and high 69.97.

Peers on Argus

TNXP was up 0.29% while close peers showed mixed moves: ANNX and VNDA up, CADL a...

1 Up

TNXP was up 0.29% while close peers showed mixed moves: ANNX and VNDA up, CADL and OMER down. Momentum scanners only flagged NGNE modestly higher, pointing to stock-specific drivers rather than a coordinated biotech move.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Exchange uplisting	Positive	-0.3%	Approval to transfer listing to the Nasdaq Global Select Market.
Feb 25	Investor conferences	Positive	+3.9%	Announcements of March investor conference participation and webcast access.
Jan 30	Phase 3 data	Positive	-5.4%	Presentation of positive Phase 3 RESILIENT TONMYA data at pain summit.
Jan 06	Investor conferences	Positive	+0.9%	CEO presentations and meetings at January 2026 investor conferences.
Dec 29	Equity offering	Negative	+0.1%	Pricing of <b>$20.0M</b> registered direct offering to fund operations.

Pattern Detected

News often elicits mixed reactions: positive clinical and uplisting updates previously saw negative moves, while conference participation produced small gains. Dilutive offering news drew only a slight positive reaction.

Recent Company History

Over the past few months, Tonix has advanced TONMYA with positive Phase 3 RESILIENT data and strengthened its capital position via a $20.0M registered direct offering. The company increased visibility through multiple investor conferences and an uplisting to the Nasdaq Global Select Market on Mar 03, 2026. Against this backdrop, the new pharmacokinetic publication further details TONMYA’s profile, building on prior efficacy data and commercialization progress in fibromyalgia.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-04

The company has an active S-3/A shelf registration filed on 2025-09-04. It has been used at least once, as indicated by a 424B5 filing on 2025-11-21, providing a framework for potential future registered offerings.

Market Pulse Summary

This announcement details pharmacokinetic studies showing TONMYA’s sublingual formulation achieved r...

Analysis

This announcement details pharmacokinetic studies showing TONMYA’s sublingual formulation achieved rapid transmucosal absorption, 154% relative bioavailability, and a 783% higher early AUC vs oral cyclobenzaprine. These data support the rationale for reduced norcyclobenzaprine exposure and potentially more durable analgesic effects in fibromyalgia. In context of recent Phase 3 results, uplisting, and earlier financing, investors may watch how such mechanistic publications influence prescribing behavior and longer-term commercialization of this first-in-15-years fibromyalgia treatment.

Key Terms

pharmacokinetic, transmucosal absorption, first-pass liver metabolism, active metabolite, +4 more

8 terms

pharmacokinetic medical

"Announces Publication of Clinical Pharmacokinetic Studies of TONMYA"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

transmucosal absorption medical

"achieved the design objectives of rapid transmucosal absorption and bypassing"

Transmucosal absorption is the process by which a drug or compound is taken up through the body's mucous membranes (for example inside the mouth, nose, or rectum) and enters the bloodstream instead of going through the stomach and liver. Like taking a shortcut, this route can make medicines act faster, be easier to take, and avoid breakdown in the gut, factors that affect dosing, patient convenience, regulatory hurdles and the commercial competitiveness of a therapy.

first-pass liver metabolism medical

"absorption and bypassing first-pass liver metabolism"

First-pass liver metabolism is the process by which a drug or orally taken substance is broken down by the liver before it reaches the general circulation, reducing the amount that can have an effect in the body. For investors, this matters because high first-pass metabolism can lower a pill’s effective dose, require higher or more frequent dosing, complicate development and regulatory approval, and affect a product’s marketability and cost, much like a toll that shrinks the value of goods before they reach customers.

active metabolite medical

"decrease production of the active metabolite norcyclobenzaprine"

An active metabolite is a chemical that a body creates when it breaks down a drug, and that chemical itself has medicinal effects. Think of the original drug as raw ingredients and the active metabolite as the finished dish that actually delivers flavor — sometimes the metabolite does most of the work, lasts longer, or causes side effects. For investors, knowing whether a drug relies on active metabolites matters because it affects dosing, safety, regulatory review, market value, and how competing drugs or interactions might change a product’s commercial prospects.

sublingual medical

"cyclobenzaprine HCl sublingual tablets) for long-term daily dosing"

Sublingual describes a way to take a drug or supplement by placing it under the tongue so active ingredients are absorbed through the thin tissue there directly into the bloodstream. Like taking a shortcut compared with swallowing a pill, this can produce faster effects, simpler dosing and sometimes more predictable delivery. Investors watch for sublingual formulations because they can affect a product’s market appeal, regulatory pathway, pricing and competitive positioning.

open-label medical

"Results From Randomized, Open-Label Studies in Healthy Volunteers"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

bioavailability medical

"showed rapid absorption and increased relative bioavailability compared with oral IR"

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

AUC medical

"and a 783% higher dose-normalized AUC during the first hour post-dose"

Area under the curve (AUC) measures the total exposure of the body to a drug over time by calculating the area beneath a plot of drug concentration versus time. For investors, AUC indicates how much of a medicine reaches and stays in the bloodstream, which affects dosing, safety and effectiveness—similar to measuring how much water flows through a pipe over a day rather than just its peak pressure.

AI-generated analysis. Not financial advice.

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years

The sublingual TONMYA tablet containing a basifying agent achieved the design objectives of rapid transmucosal absorption and bypassing first-pass liver metabolism

TONMYA was designed to decrease production of the active metabolite norcyclobenzaprine, which is believed to improve the durability of analgesic response in fibromyalgia relative to the transient (~1 month) effects of oral, swallowed cyclobenzaprine

BERKELEY HEIGHTS, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced the publication of a paper, “Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers,” in Clinical Pharmacology in Drug Development, the peer-reviewed journal of the American College of Clinical Pharmacology (ACCP). TONMYA™ was investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets) and approved by the U.S. Food and Drug Administration (FDA) on August 15, 2025, for the treatment of fibromyalgia in adults. The manuscript can be accessed at: https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.70034.

"These data demonstrate the importance of the proprietary basifying agent in TONMYA's sublingual formulation," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "An earlier study conducted by Tonix showed that transmucosal delivery cannot be achieved by simply applying a liquid cyclobenzaprine HCl formulation under the tongue. Due to the basifying agent ingredient, sublingual TONMYA achieves rapid transmucosal absorption that bypasses first-pass hepatic metabolism. This pharmacokinetic profile underpins TONMYA's unique sublingual formulation, which is designed to increase parent drug exposure during sleep while reducing exposure and side effects to the long half-life, active metabolite.”

Dr. Lederman continued, “Bedtime oral swallowed cyclobenzaprine was one of the first drugs studied as a treatment for fibromyalgia, but it failed because the benefits were only transient (~1 month) and fibromyalgia is a chronic condition requiring durable responses.¹ Our design objective for TONMYA was to improve the durability of cyclobenzaprine’s treatment effect by decreasing liver production of the major active metabolite norcyclobenzaprine, which we believe counteracted the benefits of swallowed cyclobenzaprine over time. We believe the clinical pharmacology studies published in Clinical Pharmacology in Drug Development, show that TONMYA achieved this design objective. Later studies^2,3 confirmed that TONMYA as a daily bedtime medicine provides a durable analgesic benefit to fibromyalgia patients and is generally well tolerated."

The publication reports findings from two Phase 1 single-dose, open-label studies conducted in healthy adult volunteers.

In Study 1 (n=24), three sublingual formulations of cyclobenzaprine HCl 2.8 mg, each containing a different basifying agent, were compared with oral immediate-release (IR) cyclobenzaprine HCl 5 mg under fasting conditions. All sublingual formulations showed rapid absorption and increased relative bioavailability compared with oral IR cyclobenzaprine HCl. The potassium phosphate dibasic formulation (designated TNX-102 SL) demonstrated the most favorable pharmacokinetic profile, with a 154% relative bioavailability compared to oral IR, an absorption lag of approximately 3 minutes versus approximately 37 minutes for oral IR, and a 783% higher dose-normalized AUC during the first hour post-dose. Based on these results, the potassium phosphate dibasic formulation was selected for further clinical development.

In Study 2 (n=16), TNX-102 SL 2.8 mg and 5.6 mg were evaluated in a crossover design under fasting and fed conditions. The formulation exhibited dose proportionality between the two dose levels, and pharmacokinetic parameters were not affected by a high-calorie, high-fat meal, confirming the absence of a food effect. This study also provided a full clinical characterization of the active metabolite norcyclobenzaprine, demonstrating an elimination half-life of approximately 60 hours. Reduced exposure to norcyclobenzaprine following sublingual administration, as compared with oral delivery, is believed to contribute to the improved durability of efficacy and favorable tolerability profile observed with TONMYA in Phase 3 fibromyalgia studies.^2,3

Across both studies, single-dose sublingual cyclobenzaprine HCl was generally well tolerated. All treatment-emergent adverse events were mild or moderate in severity. The most commonly reported adverse events were oral hypoesthesia and abnormal taste. No serious adverse events were reported, and no clinically meaningful changes were observed in laboratory parameters, vital signs, or electrocardiogram findings.

Citations

¹Carette S, et al. Arthritis Rheum. 1994. 37(1):32-40. doi: 10.1002/art.1780370106.
²Lederman S, et al. Arthritis Care Res (Hoboken). 2023. 75(11):2359-2368. doi: 10.1002/acr.25142.
³Lederman S, et al. Pain Med. 2026. 27(1):86-94. doi: 10.1093/pm/pnaf089.

About Fibromyalgia

Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 6-12 million adults in the U.S., approximately 90% of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed products.

About TONMYA™ (cyclobenzaprine HCl sublingual tablets)

TONMYA (cyclobenzaprine HCl sublingual tablets) is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a multifunctional agent with potent binding and antagonist activities at the 5-HT_2A serotonergic, α₁-adrenergic, H₁-histaminergic, and M₁-muscarinic receptors, TONMYA was approved on August 15, 2025, by the FDA for the treatment of fibromyalgia in adults. TONMYA is the first new prescription medicine approved for fibromyalgia in more than 15 years. TONMYA was investigated as TNX-102 SL. TNX-102 SL is also being developed to treat acute stress reaction (ASR)/acute stress disorder (ASD), and major depressive disorder (MDD). The United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent No. 10,357,465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix’s proprietary TONMYA composition. These patents are expected to provide TONMYA with U.S. market exclusivity until 2034/2035.

Tonix Pharmaceuticals Holding Corp.*

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace^® SymTouch^® and Tosymra^®. Tonix is maximizing the science behind TNX-102 SL in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals 
(862) 799-8599 
investor.relations@tonixpharma.com 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contacts
Deborah Elson
Tonix Pharmaceuticals 
deborah.elson@tonixpharma.com

Ray Jordan 
Putnam Insights 
ray@putnaminsights.com 

INDICATION
TONMYA is indicated for the treatment of fibromyalgia in adults.

CONTRAINDICATIONS
TONMYA is contraindicated:
In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected. With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.
During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. In patients with hyperthyroidism.

WARNINGS AND PRECAUTIONS
Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.

Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.

Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.

Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.

CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities. Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS
MAO inhibitors: Life-threatening interactions may occur.

Other serotonergic drugs: Serotonin syndrome has been reported.

CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.

Tramadol: Seizure risk may be enhanced.
Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.

USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).

Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of TONMYA have not been established.

Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.

Please see additional safety information in the full Prescribing Information.
To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

FAQ

What did Tonix report about TONMYA (TNX-102 SL) pharmacokinetics in March 2026?

The studies showed rapid sublingual absorption and increased parent exposure versus oral IR. According to the company, TNX-102 SL achieved 154% relative bioavailability, ~3-minute absorption lag, and a 783% higher dose-normalized AUC during the first hour.

How does TONMYA's absorption compare to oral immediate-release cyclobenzaprine (TNXP)?

TONMYA achieves much faster transmucosal uptake and greater early exposure. According to the company, absorption lag was ~3 minutes versus ~37 minutes for oral IR, with 154% relative bioavailability and markedly higher first-hour AUC.

Does food affect TONMYA (TNX-102 SL) pharmacokinetics for TNXP?

No meaningful food effect was observed in Phase 1 studies. According to the company, pharmacokinetic parameters were unchanged after a high‑calorie, high‑fat meal, supporting dosing without regard to meals.

What is known about the active metabolite norcyclobenzaprine for TONMYA (TNXP)?

The studies characterized norcyclobenzaprine elimination and exposure differences. According to the company, norcyclobenzaprine had an elimination half-life of approximately 60 hours, and sublingual dosing reduced metabolite exposure versus oral delivery.

What safety findings were reported for TONMYA (TNX-102 SL) in the published studies?

Single-dose sublingual doses were generally well tolerated with mostly mild or moderate events. According to the company, no serious adverse events occurred; the most common events were oral hypoesthesia and abnormal taste.